Welcome to our dedicated page for Takeda Pharm news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharm stock.
Takeda Pharmaceutical Company Limited reports news as a Japan-based, R&D-driven biopharmaceutical company whose American depositary shares trade under TAK. Its updates center on medicines and pipeline programs in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, including ENTYVIO, GAMMAGARD LIQUID ERC, HYQVIA, TAK-881, zasocitinib, rusfertide and oveporexton.
Recurring developments include pivotal clinical trial data, U.S. FDA regulatory actions involving new drug applications, prescription product availability, collaboration updates, and financial reports. Takeda also reports on launch preparation, generic competition affecting established products, operating-cost discipline, foreign-exchange effects, corporate transformation initiatives and governance matters tied to its global pharmaceutical business.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has finalized the sale of a portfolio of around 130 OTC and prescription products to Orifarm Group for up to $670 million USD. This portfolio, which generated FY2020 net sales of approximately $240 million USD, includes key products from various therapeutic areas mainly sold in Europe. Proceeds will be used to reduce debt, aiming for a 2x net debt/adjusted EBITDA target by 2023. The transaction has also involved transitioning approximately 600 employees to Orifarm.
Takeda Pharmaceutical Company has completed the sale of its Consumer Healthcare division to Blackstone for JPY 242 billion. The divestiture includes numerous OTC products generating over JPY 60 billion in revenue. Following the sale, TCHC will operate as Alinamin Pharmaceuticals. Takeda aims to use the proceeds to reduce debt and achieve a net debt/EBITDA ratio of 2x by FY2023. With this transaction, Takeda has surpassed its $10 billion divestiture target, totaling $12.9 billion since January 2019. A pre-tax gain of JPY 140 billion will boost reported net profit for FY2020.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced that the European Medicines Agency (EMA) accepted its regulatory filings for the dengue vaccine candidate, TAK-003. This vaccine is aimed at preventing dengue in individuals aged four to 60. Takeda plans to submit filings in multiple countries including Argentina, Brazil, and Mexico in 2021. The company is also participating in EMA’s parallel assessment assessment process. The pivotal Phase 3 trial demonstrated safety and efficacy over 36 months, highlighting the urgent need for dengue vaccination globally.
Takeda Pharmaceutical presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation the results from the Phase 3 SOLSTICE trial of TAK-620 (maribavir). The study demonstrated a significant increase in CMV viremia clearance among transplant recipients with resistant infections, achieving 62.8% with maribavir against 20.3% with conventional therapies. Maribavir also exhibited lower rates of treatment-related toxicities compared to traditional antiviral options, highlighting its potential as a transformative treatment for CMV infections in transplant patients.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has partnered with IDT Biologika to temporarily use its manufacturing capacity for the COVID-19 vaccine developed by Janssen Pharmaceuticals. This arrangement allows Takeda to support global vaccination efforts while ensuring that its dengue vaccine candidate, TAK-003, can resume production shortly after. The company remains dedicated to addressing both COVID-19 and dengue, acknowledging the significant public health needs associated with these diseases.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has submitted a New Drug Application (NDA) for lanadelumab, a monoclonal antibody therapy, to the MHLW in Japan. This treatment targets hereditary angioedema (HAE), a rare genetic disorder affecting 2,000-3,000 people in Japan, of whom only 450 are diagnosed. Lanadelumab proved effective in reducing monthly HAE attacks by up to 87% in clinical trials. If approved, it will be available as a pre-filled syringe, enhancing treatment access for patients with unmet medical needs.
Takeda Pharmaceutical Company Limited (TAK) aims for over JPY 1 trillion (approx. US$9 billion) in revenue from its Growth and Emerging Markets Business Unit by FY2030, signaling more than double its current revenues. This growth strategy focuses on key markets like Brazil, China, and India, with over 20% expected annual growth in China. Takeda plans to enhance access to innovative therapies, including a dengue vaccine candidate (TAK-003), to address unmet patient needs. The company emphasizes a patient-centric approach while maintaining a commitment to local health systems.
BioLife Plasma Services, a division of Takeda, announced the opening of a new plasma donation center in Deptford, New Jersey, to address the rising demand for plasma donations, particularly due to the pandemic. This center will generate approximately $2-3 million annually through donor compensation and create 60 jobs in the community. The facility is part of a network of over 140 centers, known for their high safety standards, and aims to provide essential therapies for patients with rare conditions. The center opens on March 13, and strict health measures are in place to ensure donor safety.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced its decision to acquire Maverick Therapeutics, Inc., specializing in bispecific T-cell targeted immunotherapies. This acquisition includes Maverick's COBRA™ platform and key candidates like TAK-186 and TAK-280, aimed at treating specific solid tumors. The transaction, valued up to $525 million, hinges on antitrust reviews and is anticipated to finalize in Q1 of Takeda's fiscal year 2021. This strategic move enhances Takeda's oncology portfolio and development capabilities, strengthening its commitment to innovative cancer treatments.
Takeda Pharmaceutical Company and Ovid Therapeutics announced an exclusive agreement for Takeda to gain global rights to develop and commercialize soticlestat for treating developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome. Takeda will pay Ovid $196 million upfront and could pay up to $660 million in milestones. This agreement relieves Ovid from further financial obligations related to the original collaboration. Phase 3 studies are set to begin in Q2 2021, building on positive Phase 2 ELEKTRA study results.